ResearcherSecond Affiliated Hospital of Zhejiang UniversityActive in the last 2 years

Zhongkun Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0009-1192-3322; OpenAlex author ID A5068350215. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2024: 1 paper · 2025: none · 2026: 1 paper

Papers 2

Targeting DGAT1 reprograms lipid landscape and restores CD8⁺ T cell immunity in pancreatic cancer. Co-author DOI 10.1038/s41467-026-74315-2 ↗
Receptor-interacting Protein Kinase 2 Is an Immunotherapy Target in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-23-0584 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yunhua Liu · 2 shared papers, 2024–2026 · strength 0.43
- Paper Targeting DGAT1 reprograms lipid landscape and restores CD8⁺ T cell immunity in pancreatic cancer. DOI 10.1038/s41467-026-74315-2 ↗
- Paper Receptor-interacting Protein Kinase 2 Is an Immunotherapy Target in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-23-0584 ↗
Qi Zhang · 1 shared paper, 2026 · strength 0.25
- Paper Targeting DGAT1 reprograms lipid landscape and restores CD8⁺ T cell immunity in pancreatic cancer. DOI 10.1038/s41467-026-74315-2 ↗
Hong Jiang · 1 shared paper, 2024 · strength 0.18
- Paper Receptor-interacting Protein Kinase 2 Is an Immunotherapy Target in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-23-0584 ↗
Wenhua Sang · 1 shared paper, 2024 · strength 0.18
- Paper Receptor-interacting Protein Kinase 2 Is an Immunotherapy Target in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-23-0584 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.